Unleashed From the Nucleus, TDP-43 Wreaks Havoc in Mitochondria
Loose in the cytoplasm, TDP-43 heads straight for the neuronal powerhouses, sapping their ability to make energy.
6401 RESULTS
Sort By:
Loose in the cytoplasm, TDP-43 heads straight for the neuronal powerhouses, sapping their ability to make energy.
Seeking strength in numbers, families gathered to swap stories and to learn about an upcoming DIAN-TU therapy trial geared specifically to their particular form of early onset AD.
Microglia and macrophages lacking the receptor consumed less amyloid in vitro, even when stimulated by anti-Aβ antibodies.
A bill approved by the U.S. House Committee on Appropriations would increase funding for Alzheimer’s by $350 million.
At Keystone, researchers report the discovery of ion channels that shed light on the machinations of the brain’s microglia.
Researchers are discovering that microglia not only respond dramatically to their environment, but they also can quickly lose their identity.
A PET study comparing amyloid, tau, and volumetric imaging in preclinical AD identifies a region where local tangles correlate with brain-wide amyloid.
At Keystone, researchers also linked the receptor to microglial homeostasis and migration, and resolved lingering questions about TREM2’s role in plaque clearance.
Four researchers received awards totaling $350,000 for their contributions to Alzheimer’s research.
Antisense oligonucleotides can flip expression of tau from the three-repeat to the four-repeat form. These ASOs triggered tau aggregation and behavioral problems.
In First Phase 3 Trial, the Tau Drug LMTM Did Not Work. Period. Staging of Alzheimer’s, the Second: Neurodegeneration Does Not Equal Tauopathy Coming to a Center Near You: GAP and EPAD to Revamp Alzheimer’s Trials Access: How to Bring People in ‘From the
Scientists pool samples and creatively mine the genomes of thousands of patients to find coding and non-coding variants that associate with the disease.
This past year, the Global Alzheimer’s Platform and the European Prevention of Alzheimer’s Dementia have moved quickly, and jointly, to pave the way toward more, faster, cheaper trials. Will they be better, too?
Alarmed by crushing screen failure rates of the first prodromal Alzheimer’s trials, EPAD and GAP are chasing new ways to reach people who don’t know they really should be in a secondary prevention trial.
Clinical trial centers are preparing to position themselves as standing networks, with standardized paperwork, clinical rater systems, and a central IRB, for trials anticipated to start late next year.